Recently, the serum HE4 has been identified as a diagnostic and prognostic biomarker for lung cancer, lung malignancies, ovarian carcinoma, and endometrial carcinomas [16, 17]. This evidence concerns the gene WFDC2 and endometrial carcinoma.